| Next 10 |
GBT News and Press, Global Blood Therapeutics Inc.
-
SOUTH SAN FRANCISCO, Calif. and LONDON, June 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments for underserved patient communities, announced toda...
-
Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation Two Real-world Data Studies Demonstrated Sustained Improvements in Hemoglobin with Oxbryta Consistent with Results from the Phase 3 HOPE Study SOUTH SAN FRANCISCO, Calif., June 11, 2021 (GLOBE NEWSWIRE)...
-
Global Blood Therapeutics (GBT) says that on June 1, 2021, the compensation committee of GBT's board granted 11 new employees options to purchase an aggregate of 35,500 shares of the company's common stock at $37.20/share and restricted stock units for an aggregate of 45,410 shares of th...
-
SOUTH SAN FRANCISCO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 8, 2021, at 2:10 p.m...
-
SOUTH SAN FRANCISCO, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that six abstracts related to its sickle cell disease (SCD) programs will be presented at the European Hematology Association (EHA) 2021 Virtual Congress ...
-
Beyond the initial approval, the company is seeking Oxbryta label expansion as well as approval in the European Union. The company is increasing its focus on sickle cell disease by advancing inclacumab into two Phase 3 trials as well as generating proof-of-concept data for GBT-601. ...
-
Shares of Global Blood Therapeutics (NASDAQ: GBT) were sinking 8% as of 11:14 a.m. EDT on Thursday. The decline came after the company announced its first-quarter results following the market close on Wednesday. Global Blood Therapeutics reported net sales of $39 million in the ...
-
Image source: The Motley Fool. Global Blood Therapeutics (NASDAQ: GBT) Q1 2021 Earnings Call May 05, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Global Blood Therapeutics (GBT) Q1 2021 Earnings Call Transcript ...
-
Global Blood Therapeutics, Inc. (GBT) CEO Dr. Ted Love on Q1 2021 Results - Earnings Call Transcript
Global Blood Therapeutics, Inc. (GBT) Q1 2021 Results Conference Call May 05, 2021 04:30 PM ET Company Participants Steven Immergut - SVP, Head of Corporate Communications and IR Dr. Ted Love - President and Chief Executive Officer Jeff Farrow - Chief Financial Officer David Johnson - Chief C...
-
Global Blood Therapeutics (GBT): Q1 GAAP EPS of -$1.21 misses by $0.20.Revenue of $39.04M (+176.5% Y/Y) misses by $3.96M.Shares -2.33%.Press Release For further details see: Global Blood Therapeutics EPS misses by $0.20, misses on revenue
Stock Information
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
MENU
GBT
GBT Quote
GBT Short
GBT News
GBT Articles
Get GBT Alerts
News, Short Squeeze, Breakout and More Instantly...
-
SOUTH SAN FRANCISCO, Calif. and LONDON, June 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments for underserved patient communities, announced toda...
-
Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation Two Real-world Data Studies Demonstrated Sustained Improvements in Hemoglobin with Oxbryta Consistent with Results from the Phase 3 HOPE Study SOUTH SAN FRANCISCO, Calif., June 11, 2021 (GLOBE NEWSWIRE)...
-
SOUTH SAN FRANCISCO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 8, 2021, at 2:10 p.m...